BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Moderate Buy” from Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has received an average rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $378.4286.

A number of research firms have weighed in on ONC. Morgan Stanley reaffirmed an “overweight” rating and set a $405.00 price target on shares of BeOne Medicines in a research note on Thursday, January 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $420.00 target price on shares of BeOne Medicines in a research report on Monday, November 17th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Citizens Jmp raised their price objective on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research note on Wednesday, December 17th.

BeOne Medicines Stock Up 0.2%

ONC opened at $339.32 on Friday. BeOne Medicines has a 12 month low of $196.45 and a 12 month high of $385.22. The business has a 50-day moving average of $328.39 and a two-hundred day moving average of $319.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17. The stock has a market capitalization of $37.21 billion, a price-to-earnings ratio of 665.33 and a beta of 0.47.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 996 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $349.17, for a total transaction of $347,773.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Xiaobin Wu sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $356.02, for a total transaction of $3,560,200.00. Following the completion of the transaction, the chief operating officer directly owned 6,009 shares in the company, valued at approximately $2,139,324.18. This represents a 62.46% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 128,610 shares of company stock valued at $41,114,068. 6.62% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in BeOne Medicines in the second quarter valued at $13,857,000. Slow Capital Inc. acquired a new position in BeOne Medicines during the 2nd quarter worth $4,377,000. Virtus Investment Advisers LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter worth about $389,000. Baird Financial Group Inc. bought a new stake in shares of BeOne Medicines in the 2nd quarter worth about $82,895,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $3,491,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.